Please select the option that best describes you:
Do you recommend using BRAFV600E mutation status to risk stratify treatment for a pediatric patient with langerhans cell histiocytosis?
Answer from: at Community Practice
It’s certainly useful information. Even if you don’t use a BRAF inhibitor as first line therapy, you will have that option in your back pocket.
Sign in or Register to read more